These innovative compounds represent a significant advancement in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://woodyiuqc114204.free-blogz.com/86422941/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide